Table 1 Demographics of the patients (N = 120) and biopsies (N = 141).

Mean patient age (median, range) in years

43 (41, 19–83)

40 (39, 31–50)

Patient gender (% male)

51 (54% male, 17 NA)

4 (50% male, 2 NA)

Diagnosis

Ulcerative colitis (UC)

112

0

Inflammatory bowel disease unclassified (IBDU)

0

8

Centers

University of Alberta Hospital – Edmonton

95

6

Cedars-Sinai Medical Center – Los Angeles

17

2

Median time from index to last known follow-up in months (mean)

5.1 (4.7)

6.2 (6.2)

Endoscopy and biopsy indication

New diagnosis

5

-

Disease activity assessment

73

6

Dysplasia screening

6

1

Fecal microbiota transplant

1

-

Cancer screening

2

-

NA

41

6

Disease extent

Remission

57

5

Proctitis

11

1

Left-sided

26

4

Extensive

4

-

Pancolitis

22

1

NA

8

2

Endoscopic Mayo subscore at biopsy location

0

24

1

1

30

3

2

45

4

3

29

5

Treatment regimen at the time of the biopsy^a

5-aminosalicylic acid (topical or oral)

62

4

Biologic

27

3

Immunomodulator^b

30

4

Infliximab

16

1

Adalimumab

4

2

Golimumab

2

-

Vedolizumab

4

-

Other therapy

8

2